Clinical trials: Pharmacology
Solid Tumors
A Phase I Pharmacologic Study of CYC116, an Oral Aurora Kinase Inhibitor, in Patients With Advanced Solid Tumors
This is a phase I study of an investigational cancer drug, CYC116, in patients with advanced solid tumors.
- Trial name
- NCT00560716
- Testing
- CYC116
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- Cyclacel Pharmaceuticals, Inc.
Submental Fat (SMF), Double Chin
RJV001 Study in Adults Receiving Abdominoplasty
In this study, we are testing a new drug against submental fat (SMF), which is characterized with the accumulation of fat under the chin that often appears as a "double chin".
- Trial name
- NCT04821648
- Testing
- RJV001
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Rejuven Dermaceutical Co., Ltd.
Solid Cancers
A Study of the Safety and Pharmacology of MEGF0444A in Combination With Bevacizumab With or Without Paclitaxel in Patients With Locally Advanced or Metastatic Solid Tumors
This is a Phase Ib, open-label, dose-escalation study of MEGF0444A in combination with bevacizumab, and in combination with bevacizumab and paclitaxel as therapy for locally advanced or metastatic solid tumors.
- Trial name
- NCT01075464
- Testing
- MEGF0444A, bevacizumab, paclitaxel
- Where
- 5 sites in United States
- Volunteers
- 64 people
- Sponsor
- Genentech, Inc.
Renal Impairment, Healthy Participants
Safety and Pharmacokinetics of Linzagolix in Female Subjects With Normal and Impaired Renal Function
The primary objective of this study is to assess the pharmacokinetics (PK) of linzagolix in subjects with varying degrees of impaired renal function compared to matched control subjects with normal renal function
- Trial name
- NCT03961932
- Testing
- Linzagolix
- Where
- 2 sites in United States
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- ObsEva SA
Cancer
Safety and Pharmacology Study of SNX-5422 in Subjects With Refractory Hematological Malignancies
Hsp90 is a chemical in the body that is involved int he promotion of cancer. SNX-5422 is an experimental drug that blocks Hsp90.
- Trial name
- NCT01635712
- Testing
- SNX-5422
- Where
- 5 sites in United States
- Volunteers
- 10 people
- Sponsor
- Esanex Inc.
Healthy Participants
A Comparative Study to Evaluate the Effects and Mechanism of Action of Dysport®, Botox® and Xeomin® in the Extensor Digitorum Brevis Model in Healthy Adult Male Participants
Study aimed at comparing the pharmacodynamic profile (including duration of action) of three commercialized toxins by measuring the action potential of the injected muscle (extensor digitorum brevis)
- Trial name
- NCT04970407
- Testing
- Botulinum toxin type A
- Where
- United Kingdom
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Ipsen
Atrial Fibrillation
A Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of HSY244 in Participants With Atrial Fibrillation
This was a randomized, placebo-controlled, investigator- and participant-blinded study to evaluate the efficacy, safety, tolerability, and pharmacokinetics (PK) of HSY244 in participants with atrial fibrillation (AF), with and…
- Trial name
- NCT04582409
- Testing
- HSY244
- Where
- 4 sites in United States, Germany
- Volunteers
- 13 people
- Sponsor
- Novartis Pharmaceuticals
Psoriasis, Plaque Psoriasis
A Study to Determine the Efficacy and Safety of Halobetasol Propionate Lotion 0.05% in Subjects With Plaque Psoriasis
This is a double-blind, multicenter, vehicle-controlled, parallel group comparison study to determine and compare the efficacy and safety of HBP Lotion 0.05% and Vehicle Lotion applied twice daily for two weeks in subjects with…
- Trial name
- NCT01610596
- Testing
- Halobetasol Propionate Lotion 0.05%
- Where
- 3 sites in United States
- Volunteers
- 72 people
- Sponsor
- Therapeutics, Inc.
Major Depressive Disorder
A Study of LY03005 vs Pristiq
The objective of this study is to evaluate relative bioavailability between 80 mg LY03005 oral tablets and 50 mg Pristiq® oral tablets after a single dose of each drug in a cross-over 2-period design under fasting condition in…
- Trial name
- NCT03733574
- Testing
- LY03005, Pristiq
- Where
- United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Luye Pharma Group Ltd.
Healthy Adult Males
A Clinical Pharmacology Study of MT-3921 in Healthy Adult Males
The purpose of this study is to investigate the safety, tolerability, and pharmacokinetics when MT-3921 or a placebo is intravenously given to Japanese healthy adult male subjects
- Trial name
- NCT05396235
- Testing
- MT-3921
- Where
- Japan
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Tanabe Pharma Corporation
Hepatitis C Virus Infection
Efficacy and Safety of Sofosbuvir/Velpatasvir ± Ribavirin for 12 Weeks in Adults With Chronic HCV Infection and Decompensated Cirrhosis
The primary objectives of this study are to evaluate the antiviral efficacy, safety, and tolerability of sofosbuvir/velpatasvir (SOF/VEL) fixed-dose combination (FDC) with or without ribavirin (RBV) for 12 weeks in adults with…
- Trial name
- NCT02996682
- Testing
- SOF/VEL, RBV
- Where
- 33 sites in Japan
- Volunteers
- 102 people
- Sponsor
- Gilead Sciences
Healthy Subject
A Clinical Pharmacology Study of Bardoxolone Methyl in Healthy Adults
Food effect part: To investigate the effect of food on the pharmacokinetics of RTA 402 and evaluate the safety of RTA 402 in Japanese healthy male adults, using the capsule formulations.
- Trial name
- NCT04023903
- Testing
- Bardoxolone methyl
- Where
- Japan
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Kyowa Kirin Co., Ltd.
In Vitro Fertilization
A Trial of Single Dose Corifollitropin Alfa's Ability to Induce Multiple Follicular Growth During the First Week of Controlled Ovarian Stimulation for IVF or ICSI (38833)(P05788)
To evaluate the induction of multiple follicular growth after single dose administration of 100 μg or 150 μg Org 36286 in a long protocol of GnRH agonist.
- Trial name
- Realize (NCT00702351)
- Testing
- Org 36286 (corifollitropin alfa)
- Volunteers
- 50 people
- Sponsor
- Organon and Co
Schizophrenia
A Clinical Pharmacology Trial of Brexpiprazole Long Acting Injectable (LAI) Administered as a Single Dose in Patients With Schizophrenia
The purpose of this study is to determine the pharmacokinetics (PK), tolerability and safety of brexpiprazole LAI following a single administration in subjects with schizophrenia.
- Trial name
- NCT05119894
- Testing
- Brexpiprazole LAI: Dose 1, Brexpiprazole LAI: Dose 2, Brexpiprazole LAI: Dose 3
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Healthy
Effect of Evobrutinib on Pharmacokinetics of a Combined Oral Contraceptive
The purpose of this study was to assess the effect of M2951 on the pharmacokinetics (PK) of a combined oral contraceptive [Ethinyl estradiol/Norethisterone (EE/NET)] in healthy female participants.
- Trial name
- NCT07215806
- Testing
- Evobruitnib, Combined oral contraceptive [ethinyl estradiol/ norethisterone (EE/NET)]
- Where
- Germany
- Volunteers
- 20 people
- Sponsor
- Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Congestive Heart Failure
A Study Investigating the Safety, Tolerability, and Pharmacokinetics of MTP-131 in Subjects With Congestive Heart Failure
This is a Phase 1, single-center, randomized, double-blind, single ascending dose, placebo-controlled study, in subjects aged 45-80 years with stable mild to moderate heart failure due to left ventricular systolic dysfunction, to…
- Trial name
- NCT02388464
- Testing
- MTP-131
- Where
- Bulgaria
- Volunteers
- 36 people
- Sponsor
- Stealth BioTherapeutics Inc.
Metabolic Dysfunction-Associated Steatotic Liver Disease
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
The main purpose of the SYNERGY-OUTCOMES study is to find out whether retatrutide and tirzepatide can prevent major adverse liver outcomes (MALO) in people with high-risk metabolic dysfunction-associated steatotic liver disease…
- Trial name
- NCT07165028
- Testing
- Tirzepatide, Retatrutide
- Where
- 563 sites in United States, Argentina and 32 more
- Volunteers
- 4,500 people
- Sponsor
- Eli Lilly and Company
Malignant Solid Tumor, Lymphomas
A Phase 1 Dose-Escalation Study in Advanced Solid Tumors, Lymphomas or Multiple Myeloma
Phase 1 study to determine safety, tolerability, dose-limiting toxicities (DLTs), and recommended Phase 2 dose of AV-299 administered IV as monotherapy to patients with relapsed or refractory solid tumors, lymphoma, or multiple…
- Conditions
- Malignant Solid Tumor, Lymphomas, Multiple Myeloma
- Trial name
- P05538 (NCT00725634)
- Testing
- AV-299, AV-299 + erlotinib
- Where
- 3 sites in United States
- Volunteers
- 41 people
- Sponsor
- AVEO Pharmaceuticals, Inc.
Leukemia
A Study to Investigate BAY2402234, a Dihydroorotate Dehydrogenase (DHODH) Inhibitor, in Myeloid Malignancies
The primary objective is to determine the safety, tolerability, pharmacokinetics, maximum tolerated dose (MTD), or pharmacological active dose (PAD) of BAY2402234 in patients with acute myeloid leukemia (AML), myelodysplastic…
- Trial name
- NCT03404726
- Testing
- BAY2402234
- Where
- 5 sites in United States, France
- Volunteers
- 40 people
- Sponsor
- Bayer
HER-2 Gene Amplification
A Study of MM-111 in Combination With Multiple Treatments in Patients With HER2 Positive Cancer
This study is an open-label, dose-escalation study of MM-111 with five different combination treatments with the main goal of determining the safety of MM-111 with each combination.
- Trial name
- NCT01304784
- Testing
- Cisplatin, Capecitabine, Trastuzumab and MM-111, Lapatinib +/- Trastuzumab and MM-111, Paclitaxel, Trastuzumab and MM-111
- Where
- 15 sites in United States
- Volunteers
- 100 people
- Sponsor
- Merrimack Pharmaceuticals